Table 1 Demographics and treatment history by Recurrence Pattern
From: Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior
Recurrence Pattern | p-value | Entire Cohort | ||
|---|---|---|---|---|
Liver Metastasis | Lung Metastasis | |||
Mean Age ±SD | 64 ± 11 years | 66 ± 10 years | 0.43 | |
Gender | 0.99 | |||
Male | 55 (54%) | 25 (53%) | 80 (54%) | |
Female | 47 (46%) | 22 (47%) | 69 (46%) | |
Ethnicity | 0.80 | |||
Caucasian | 86 (84%) | 41 (87%) | 127 (85%) | |
Hispanic | 5 (5%) | 1 (2%) | 6 (4%) | |
African-American | 1 (1%) | 3 (6%) | 4 (3%) | |
Asian | 5 (5%) | 1 (2%) | 6 (4%) | |
Others | 4 (4%) | – | 4 (2%) | |
N/A | 1 (1%) | 1 (2%) | 2 (2%) | |
BMI | 0.050 | |||
< 18.5 | 6 (6%) | 5 (11%) | 11 (8%) | |
18.5–24.9 | 40 (39%) | 28 (60%) | 68 (50%) | |
25–29.9 | 35 (34%) | 11 (23%) | 46 (28%) | |
30–34.9 | 15 (15%) | 3 (6%) | 18 (11%) | |
≥ 35 | 6 (6%) | – | 6 (3%) | |
Adjuvant Therapy | 0.17 | |||
Gemcitabine-based | 77 (75%) | 43 (92%) | 120 (84%) | |
Fluoropyrimidine- based | 6 (6%) | 1 (2%) | 7 (4%) | |
5-FU/Gemcitabine | 9 (9%) | 2 (4%) | 11 (6%) | |
N/A | 10 (10%) | 1 (2%) | 11 (6%) | |
Treatment Metastatic Disease | ||||
FOLFIRINOX | 18 (18%) | 5 (11%) | N/A | 23 (15%) |
Gemcitabine/Nab-paclitaxel | 9 (9%) | 1 (2%) | 10 (5%) | |
Other: Single-agent | 18 (18%) | 11 (23%) | 29 (20%) | |
Other: Multi-agent | 31 (30%) | 23 (49%) | 54 (40%) | |
N/A (Unknown) | 26 (25%) | 7 (15%) | 33 (20%) | |